Skip to main content
. 2008 Jun 19;112(5):1628–1637. doi: 10.1182/blood-2008-02-138230

Figure 3.

Figure 3

Kinetics of the JAK2V617F mutation during progression to blast phase in a patient with primary myelofibrosis. Serial analysis of marrow blast percentage and JAK2V617F mutation load showed extinction of the JAK2V617F-bearing clone during blast phase progression. In this patient, the JAK2V617F and the blast phase clones were clearly independent disease processes.